| 存储条件 |
|---|
| Product Name | CD105 [H4-A9] |
|---|---|
| Antibody Type | Primary Antibodies |
| Antigen Alias | AI528660 antibody AI662476 antibody CD 105 antibody CD105 antibody CD105 antigen antibody EGLN_HUMAN antibody END antibody Endoglin antibody Eng antibody FLJ41744 antibody HHT1 antibody ORW antibody ORW1 antibody Osler Rendu Weber syndrome 1 antibody RP11 228B15.2 antibody S-endoglin antibody SN6 antibody |
| Product description | Hereditary hemorrhagic telangiectasia (HHT) is an autosomal dominant disorder characterized by vascular abnormalities such as dilated vessels, hemorrhages, liver and lung congestion, and brain or heart ischemia. Mutations in two genes, Endoglin (also designated CD105) and ALK-1 (Activin receptor-like kinase 1, also designated TGFβ superfamily RI), are responsible for HHT. Endoglin is mutated in HHT1, and ALK-1 is mutated in HHT2, both of which are thought to be caused by haploinsufficiency. Endoglin and ALK-1 are type III and type I members of the TGFβ receptor superfamily, respectively, that are expressed on vascular endothelial cells. Endoglin can only bind ligands of the TGFβ superfamily via association with the respective ligand binding receptors for TGFβ1, TGFβ3, Activin-A, BMP-2 and BMP-7. |
| Immunogen | Recombinant protein |
| Clonality | Monoclonal |
|---|---|
| Isotype | IgG1 |
| Host Species | Mouse |
| Tested Applications | WBICCIHCFC |
| WB:1:500-1:1,000 ICC:1:100-1:500 IHC:1:100-1:500 FC:1:100-1:200 | |
| Species Reactivity | Human |
| Concentration | 2mg/ml |
| Alternative Names | AI528660 antibody AI662476 antibody CD 105 antibody CD105 antibody CD105 antigen antibody EGLN_HUMAN antibody END antibody Endoglin antibody Eng antibody FLJ41744 antibody HHT1 antibody ORW antibody ORW1 antibody Osler Rendu Weber syndrome 1 antibody RP11 228B15.2 antibody S-endoglin antibody SN6 antibody |
|---|---|
| Molecular Weight(MW) | 71 kDa |
| Cellular Localization | Membrane. |
| SwissProt ID | P17813 |
|---|
Application
Fig1: Western blot analysis of CD105 on HEK293 (1) and CD105-hIgGFc transfected HEK293 (2) cell lysate using anti-CD105 antibody at 1/1,000 dilution.
Application
Fig2: ICC staining CD105 (green) and actin filaments (red) in HepG2 cells. The nuclear counter stain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilised with 0.25% Triton X100/PBS.
Application
Fig3: Immunohistochemical analysis of paraffin-embedded human kidney cancer tissue using anti-CD105 antibody. Counter stained with hematoxylin.
Application
Fig4: Immunohistochemical analysis of paraffin-embedded human stomach cancer tissue using anti-CD105 antibody. Counter stained with hematoxylin.
Application
Fig5: Flow cytometric analysis of HepG2 cells with CD105 antibody at 1/100 dilution (green) compared with an unlabelled control (cells without incubation with primary antibody; purple).| Positive Control | CD105-hIgGFc transfected HEK293 cell lysate, HepG2, human kidney cancer tissue, human stomach cancer tissue. |
|---|---|
| Application Notes | WB:1:500-1:1,000 ICC:1:100-1:500 IHC:1:100-1:500 FC:1:100-1:200 |
| Form | Liquid |
|---|---|
| Storage Instructions | Store at +4℃ after thawing. Aliquot store at -20℃ or -80℃. Avoid repeated freeze / thaw cycles. |
| Storage Buffer | 1*TBS (pH7.4), 1%BSA, Preservative: 0.05% Sodium Azide. |
抱歉，暂无相关文献
